FDA grants breakthrough therapy designation to Merck’s MK-6482 in VHL disease-associated RCC
The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with